DLA Piper Canada advised underwriters in $316.9 million offering of Curaleaf Holdings shares

On January 12, 2021, Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf"), announced the ‎closing of an overnight marketed offering of subordinate voting shares. DLA Piper (Canada) LLP acted ‎as Canadian counsel to the underwriters on this transaction.‎

Canaccord Genuity Corp. acted as lead underwriter for the offering on behalf of a syndicate of ‎underwriters including Beacon Securities Limited, Cantor Fitzgerald Canada Corp., Cormark Securities ‎Inc., Eight Capital and Haywood Securities Inc. The underwriters exercised their over-allotment option in ‎full, and as a result 18,975,000 subordinate voting shares of the Company were issued at a price of ‎C$16.70 per share for total gross proceeds of C$316,882,500.‎

Curaleaf is a leading U.S. provider of consumer products in cannabis which operates in 23 states with 96 ‎dispensaries, 23 cultivation sites and over 30 processing sites, and ‎employs over 3,000 team members‎. ‎

The DLA Piper Canada team in this transaction was led by Robert Fonn and Derek Sigel and included ‎Catherine Kay, Grace Latimer, Lauren Storwick, Mitchell Smith, Kevin F. Fritz (Tax) and articling students Anastasia Grigoriou (Toronto) and Kevin Nelson (Calgary).‎

DLA Piper’s CBD and International Cannabis practices cover the full range of corporate, intellectual ‎property, technology and R&D, employment, regulatory and litigation matters. We're advising in every ‎segment of the pharmaceutical, biopharmaceutical, wellness and medicinal sectors around the world.‎